Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Dutta, S; Moritz, J; Pregartner, G; Thallinger, GG; Brandstätter, I; Lind, K; Rezania, S; Lyssy, F; Reinisch, A; Zebisch, A; Berghold, A; Wölfler, A; Sill, H.
Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations.
Ann Hematol. 2022; 101(4):837-846
Doi: 10.1007/s00277-022-04766-2
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Dutta Sayantanee
- Sill Heinz
- Co-authors Med Uni Graz
- Berghold Andrea
- Brandstätter Ilona
- Lind Karin
- Lyssy Freya
- Neiss Jennifer Monika
- Pregartner Gudrun
- Reinisch Andreas
- Rezania Simin
- Wölfler Albert
- Zebisch Armin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- TP53 aberrations are found in approximately 10% of patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) and are considered early driver events affecting leukemia stem cells. In this study, we compared features of a total of 84 patients with these disorders seen at a tertiary cancer center. Clinical and cytogenetic characteristics as well as immunophenotypes of immature blast cells were similar between AML and MDS patients. Median overall survival (OS) was 226 days (95% confidence interval [CI], 131-300) for the entire cohort with an estimated 3-year OS rate of 11% (95% CI, 6-22). OS showed a significant difference between MDS (median, 345 days; 95% CI, 235-590) and AML patients (median, 91 days; 95% CI, 64-226) which is likely due to a different co-mutational pattern as revealed by next-generation sequencing. Transformation of TP53 aberrant MDS occurred in 60.5% of cases and substantially reduced their survival probability. Cox regression analysis revealed treatment class and TP53 variant allele frequency as prognostically relevant parameters but not the TP53-specific prognostic scores EAp53 and RFS. These data emphasize similarities between TP53 aberrant AML and MDS and support previous notions that they should be classified and treated as a distinct disorder.
- Find related publications in this database (using NLM MeSH Indexing)
- Cytogenetics - administration & dosage
- Humans - administration & dosage
- Immunophenotyping - administration & dosage
- Leukemia, Myeloid, Acute - diagnosis, drug therapy, genetics
- Mutation - administration & dosage
- Myelodysplastic Syndromes - diagnosis, drug therapy, genetics
- Tumor Suppressor Protein p53 - genetics
- Find related publications in this database (Keywords)
- TP53
- Acute myeloid leukemia
- Myelodysplastic syndromes
- Stem cell disorder
- EAp53 and RFS score